9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

Estimated reading time: < 1 min

Condition: Mesothelioma

Estimated Enrollment: 386

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Response Rate,  Progression Free Survival,  ,

Interventions: ADI-PEG 20 plus Pem Cis, Placebo plus Pem Cis

Phase:

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Triple (Participant, Care Provider, Investigator),Primary Purpose: Treatment

Primary Completion Date: October 2020

Completion Date: June 2021

Last  Posted Date: July 19, 2019

Location: Mayo Clinic, Phoenix, Arizona, United States

Website Link: https://ClinicalTrials.gov/show/NCT02709512

Was this article helpful?
Dislike 0